Reduction in pain after treatment with Aceclofenac in osteoarthritis people

Summaries 3 min 14

Font Size

Created On: 02/08/2022

An open observational study was carried out to assess the safety and effectiveness of long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) to manage osteoarthritis pain.

See All

Key take away

Aceclofenac is well-tolerated, effective, and can be used for long-term pain alleviation in patients diagnosed with osteoarthritis.

Background

An open observational study was carried out to assess the safety and effectiveness of long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) to manage osteoarthritis pain.

Method

A total of 611 individuals with osteoarthritis (hip or knee) were incorporated. The mean age of population was 58.3 ± 11.0 yrs, with 64.5% of them being female. Aceclofenac was given to all patients at a daily dose of 200 mg. On a 10 cm visual analogue scale (VAS), movement-related pain was assessed.

The number of people with pain reduction ≥50% and the number of people with severe pain (≥6 cm by VAS) were assessed. Two weeks, three months, six months, nine months, and twelve months following the commencement of therapy, the evaluation was conducted. At each visit, side effects were recorded.

Result

As found, 53.3% of the patients had finished the trial after twelve months of follow-up. The mean pain severity was 6.5±1.2 cm VAS at baseline, 4.8±1.4 cm VAS after 2 weeks, 3.2±1.4 cm VAS after 3 months, 2.6±1.4 cm VAS after 6 months, 2.2±1.1 cm VAS after 9 months, and 1.4±1.1 cm VAS after 12 months.

From 77.8% to 24.9%, 2.9%, 2.3%, 0.9%, and 0%, the number of people having severe pain decreased. Notably, 12.0%, 65.1%, 81.0%, 88.5% and 84.0% of patients reported pain relief ≥50%. About 30% of individuals experienced side effects, mostly arterial hypertension (7.1 % to 10.9 %) and mild or moderate dyspepsia (11.1% to 23.3%). There were no significant complications noted.